Equillium Appoints New CMO, Adds Director, Renews CEO Contract
Ticker: EQ · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1746466
| Field | Detail |
|---|---|
| Company | Equillium, INC. (EQ) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-appointment, employment-agreement
Related Tickers: EQUL
TL;DR
Equillium shakes up leadership: new CMO, new board member, CEO contract renewed.
AI Summary
Equillium, Inc. announced on March 6, 2024, a series of executive and board changes. Dr. Daniel J. O'Connell has been appointed as the new Chief Medical Officer, and Mr. David M. Smith has joined the Board of Directors. Additionally, the company has entered into a new employment agreement with its Chief Executive Officer, Mr. Bruce L. Downey.
Why It Matters
These executive and board changes, along with the CEO's renewed contract, signal potential shifts in leadership strategy and operational focus for Equillium.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Equillium, Inc. (company) — Registrant
- Dr. Daniel J. O'Connell (person) — Appointed Chief Medical Officer
- Mr. David M. Smith (person) — Joined Board of Directors
- Mr. Bruce L. Downey (person) — Chief Executive Officer
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Daniel J. O'Connell has been appointed as the new Chief Medical Officer.
Who has joined the Board of Directors?
Mr. David M. Smith has joined the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is March 6, 2024.
What is Equillium, Inc.'s principal executive office address?
The principal executive office is located at 2223 Avenida de la Playa, Suite 105, La Jolla, California, 92037.
What is the filing date of this 8-K report?
The filing date is March 8, 2024.
Filing Stats: 763 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-03-08 16:01:02
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share EQ Nasdaq Capital Market
Filing Documents
- d797682d8k.htm (8-K) — 27KB
- d797682dex991.htm (EX-99.1) — 179KB
- 0001193125-24-063618.txt ( ) — 375KB
- eq-20240306.xsd (EX-101.SCH) — 3KB
- eq-20240306_lab.xml (EX-101.LAB) — 18KB
- eq-20240306_pre.xml (EX-101.PRE) — 11KB
- d797682d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Equillium, Inc. 2024 Inducement Plan and Forms of Stock Option Grant Notice, Option Agreement, and Notice of Exercise thereunder. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Equillium, Inc. Dated: March 8, 2024 By: /s/ Jason A. Keyes Jason A. Keyes Chief Financial Officer